{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:10Z","timestamp":1790409130176,"version":"4.1.0"},"reference-count":108,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-21-0205","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:17:22Z","timestamp":1654168642000},"page":"273-284","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Perspectives on the Risk-Stratified Treatment of Multiple Myeloma"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-2393","authenticated-orcid":false,"given":"Faith E.","family":"Davies","sequence":"first","affiliation":[{"name":"1Perlmutter Cancer Center, NYU Langone, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-0028","authenticated-orcid":false,"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"2Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom."},{"name":"3The Royal Marsden Hospital, Department of Haematology, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"4Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"5Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine II, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8791-1744","authenticated-orcid":false,"given":"Eileen M.","family":"Boyle","sequence":"additional","affiliation":[{"name":"1Perlmutter Cancer Center, NYU Langone, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"7Unit\u00e9 de G\u00e9nomique du My\u00e9lome, Institut Universitaire du Cancer, Toulouse France. 8Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[{"name":"9The Multiple Myeloma Research Foundation, Norwalk, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"9The Multiple Myeloma Research Foundation, Norwalk, Connecticut."},{"name":"10Multiple Myeloma Center of Excellence, Icahn School of Medicine at Mt. Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"11Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"12Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"13University Health Network and the Princess Margaret Cancer Centre, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Mayo Clinic, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin F.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"3The Royal Marsden Hospital, Department of Haematology, London, United Kingdom."},{"name":"15Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"16Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-7399","authenticated-orcid":false,"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[{"name":"17Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-2864","authenticated-orcid":false,"given":"Joseph R.","family":"Mikhael","sequence":"additional","affiliation":[{"name":"18Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Morgan","sequence":"additional","affiliation":[{"name":"19Myeloma Patients Europe, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"20Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"21Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"C. Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"22Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[{"name":"23Division of Hematology, University of Torino, Torino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Caers","sequence":"additional","affiliation":[{"name":"24Department of Hematology, Centre Hospitalier Universitaire (CHU) de Li\u00e8ge, Li\u00e8ge, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-8335","authenticated-orcid":false,"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"28Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, Indiana."},{"name":"29Department of Hematology, Mayo Clinic, Rochester, Minnesota."},{"name":"30Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"10Multiple Myeloma Center of Excellence, Icahn School of Medicine at Mt. Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-6254","authenticated-orcid":false,"given":"Brian A.","family":"Walker","sequence":"additional","affiliation":[{"name":"28Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"29Department of Hematology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"30Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"20Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"1Perlmutter Cancer Center, NYU Langone, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2025112416521411400_bib1","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2015.209","article-title":"Defining and treating high-risk multiple myeloma","volume":"29","author":"Usmani","year":"2015","journal-title":"Leukemia"},{"key":"2025112416521411400_bib2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","article-title":"Toward personalized treatment in multiple myeloma based on molecular characteristics","volume":"133","author":"Pawlyn","year":"2019","journal-title":"Blood"},{"key":"2025112416521411400_bib3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"2025112416521411400_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"2025112416521411400_bib5","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","article-title":"Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease","volume":"34","author":"Mason","year":"2020","journal-title":"Leukemia"},{"key":"2025112416521411400_bib6","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib7","doi-asserted-by":"crossref","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the Total Therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med"},{"key":"2025112416521411400_bib8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/jcm8070997","article-title":"High-risk multiple myeloma: integrated clinical and omics approach dissects the neoplastic clone and the tumor microenvironment","volume":"8","author":"Solimando","year":"2019","journal-title":"J Clin Med"},{"key":"2025112416521411400_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-021-00440-4","article-title":"Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2025112416521411400_bib11","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2025112416521411400_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"2025112416521411400_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"2025112416521411400_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib16","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ajh.24131","article-title":"Outcomes of primary refractory multiple myeloma and the impact of novel therapies","volume":"90","author":"Majithia","year":"2015","journal-title":"Am J Hematol"},{"key":"2025112416521411400_bib17","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2016.147","article-title":"Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents","volume":"30","author":"Majithia","year":"2016","journal-title":"Leukemia"},{"key":"2025112416521411400_bib18","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2013an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"key":"2025112416521411400_bib19","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1182\/bloodadvances.2020002872","article-title":"Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial","volume":"4","author":"Rana","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416521411400_bib20","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","article-title":"Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network","volume":"34","author":"Cook","year":"2020","journal-title":"Leukemia"},{"key":"2025112416521411400_bib21","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib22","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2019001275","article-title":"Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma","volume":"4","author":"Mellors","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416521411400_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"2025112416521411400_bib24","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib25","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-137021","article-title":"A new risk stratification model (R2-ISS) in newly diagnosed multiple myeloma: analysis of mature data from 7077 patients collected by European Myeloma Network within harmony big data platform","volume":"136","author":"D'Agostino","year":"2020","journal-title":"Blood"},{"key":"2025112416521411400_bib27","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","journal-title":"Haematologica"},{"key":"2025112416521411400_bib28","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib29","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"2025112416521411400_bib30","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"2025112416521411400_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib32","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/1078-0432.CCR-21-0134","article-title":"Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2,190 patients","volume":"27","author":"Zaccaria","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025112416521411400_bib33","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025112416521411400_bib34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib35","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"2025112416521411400_bib36","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.31854","article-title":"Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis","volume":"125","author":"Gambella","year":"2019","journal-title":"Cancer"},{"key":"2025112416521411400_bib37","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib38","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib39","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a Phase 2 Clinical Trial","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025112416521411400_bib40","first-page":"JCO2101935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","author":"Costa","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib41","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","article-title":"Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients","volume":"104","author":"Jones","year":"2019","journal-title":"Haematologica"},{"key":"2025112416521411400_bib42","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","journal-title":"Leukemia"},{"key":"2025112416521411400_bib43","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.17670","article-title":"High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse","volume":"195","author":"Boyle","year":"2021","journal-title":"Br J Haematol"},{"key":"2025112416521411400_bib44","article-title":"Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass Study","author":"Skerget","year":"2021","journal-title":"medRxiv"},{"key":"2025112416521411400_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib46","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.16793","article-title":"Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma","volume":"193","author":"Bygrave","year":"2021","journal-title":"Br J Haematol"},{"key":"2025112416521411400_bib47","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"key":"2025112416521411400_bib48","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.bbmt.2018.12.141","article-title":"Revised international staging system is predictive and prognostic for early relapse (&lt;24 months) after autologous transplantation for newly diagnosed multiple myeloma","volume":"25","author":"Gopalakrishnan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025112416521411400_bib49","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2015-05-644039","article-title":"Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System","volume":"126","author":"Kuiper","year":"2015","journal-title":"Blood"},{"key":"2025112416521411400_bib50","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1182\/bloodadvances.2020002838","article-title":"Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87\/NMSG-18 trial","volume":"4","author":"Kuiper","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416521411400_bib51","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib52","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"2025112416521411400_bib53","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib54","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib55","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"2025112416521411400_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib57","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-19-1507","article-title":"BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma","volume":"26","author":"Boyle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025112416521411400_bib58","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib59","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41408-019-0221-9","article-title":"Mutational processes contributing to the development of multiple myeloma","volume":"9","author":"Hoang","year":"2019","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-019-0264-y","article-title":"Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma","volume":"9","author":"Yellapantula","year":"2019","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-020-00343-w","article-title":"Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment","volume":"10","author":"Hultcrantz","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib63","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1038\/bcj.2016.1","article-title":"Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients","volume":"6","author":"Kortuem","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib64","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1038\/bcj.2016.72","article-title":"A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma","volume":"6","author":"Bolli","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib65","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025112416521411400_bib66","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"key":"2025112416521411400_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"2025112416521411400_bib68","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood.V81.12.3382.3382","article-title":"Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma","volume":"81","author":"Greipp","year":"1993","journal-title":"Blood"},{"key":"2025112416521411400_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025112416521411400_bib70","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"2025112416521411400_bib71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41375-021-01320-3","article-title":"Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length","volume":"36","author":"Boyle","year":"2022","journal-title":"Leukemia"},{"key":"2025112416521411400_bib72","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib73","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"2025112416521411400_bib74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2021-149112","article-title":"Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)","volume":"138","author":"Maura","year":"2021","journal-title":"Blood"},{"key":"2025112416521411400_bib75","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma","author":"Guerrero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112416521411400_bib76","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025112416521411400_bib77","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2025112416521411400_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"2025112416521411400_bib79","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"2025112416521411400_bib80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"2025112416521411400_bib81","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112416521411400_bib82","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2025112416521411400_bib83","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"key":"2025112416521411400_bib84","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025112416521411400_bib85","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1182\/blood-2021-148502","article-title":"Unifying the definition of high-risk in multiple myeloma","volume":"138","author":"Siegel","year":"2021","journal-title":"Blood"},{"key":"2025112416521411400_bib86","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"2025112416521411400_bib87","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025112416521411400_bib89","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025112416521411400_bib90","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"2025112416521411400_bib91","doi-asserted-by":"crossref","first-page":"e046225","DOI":"10.1136\/bmjopen-2020-046225","article-title":"MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia","volume":"11","author":"Brown","year":"2021","journal-title":"BMJ Open"},{"key":"2025112416521411400_bib92","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1200\/JCO.2021.39.15_suppl.8001","article-title":"Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum\/MUKnine trial","volume":"39","author":"Kaiser","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib93","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/bloodadvances.2020002590","article-title":"Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM","volume":"4","author":"Saini","year":"2020","journal-title":"Blood Adv"},{"key":"2025112416521411400_bib94","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"2025112416521411400_bib95","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112416521411400_bib96","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-137154","article-title":"Once weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma: high-risk cytogenetic risk planned subgroup analyses from the Phase 3 Boston Study","volume":"136","author":"Richard","year":"2020","journal-title":"Blood"},{"key":"2025112416521411400_bib97","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112416521411400_bib98","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"2025112416521411400_bib99","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2025112416521411400_bib100","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"2025112416521411400_bib101","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"2025112416521411400_bib102","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025112416521411400_bib103","doi-asserted-by":"crossref","first-page":"27854","DOI":"10.18632\/oncotarget.15718","article-title":"The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma","volume":"8","author":"Stein","year":"2017","journal-title":"Oncotarget"},{"key":"2025112416521411400_bib104","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"key":"2025112416521411400_bib105","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"2025112416521411400_bib106","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"key":"2025112416521411400_bib107","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"2025112416521411400_bib108","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-21-0205\/3162661\/bcd-21-0205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/4\/273\/3267358\/273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/3\/4\/273\/3267358\/273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:52:28Z","timestamp":1764021148000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/3\/4\/273\/705264\/Perspectives-on-the-Risk-Stratified-Treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":108,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2022,7,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0205","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.22544316","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544313","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.22544313.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.22544316.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550602","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.6550602.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}